Boehringer Ingelheim and Eli Lilly have presented positive top-line results of Jardiance (empagliflozin) from the EMPA-REG OUTCOME study in type 2 diabetes patients at high risk of cardiovascular (CV) events.

According to the firm, the study met its primary endpoint and showed superiority of Jardiance, when added to standard of care in CV reduction.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The primary endpoint was defined as time to first occurrence of either CV death or non-fatal myocardial infarction or non-fatal stroke.

Jardiance is claimed to be the only glucose-lowering agent that has demonstrated CV risk reduction in a dedicated cardiovascular outcomes trial.

"The cardiovascular risk reduction Jardiance demonstrated in the EMPA-REG OUTCOME trial is exciting."

Boehringer Ingelheim medicine global vice president professor Hans-Juergen Woerle said: "The cardiovascular risk reduction Jardiance demonstrated in the EMPA-REG OUTCOME trial is exciting and we look forward to sharing the full results."

See Also:

"Approximately 50% of deaths in people with type 2 diabetes worldwide are caused by cardiovascular disease. Reducing cardiovascular risk is an essential component of diabetes management."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

EMPA-REG OUTCOME is a multicentre, randomised, double-blind, and placebo-controlled study, which included approximately 7,000 individuals from 42 countries and observed for a median duration of 3.1 years.

The company has designed the study to evaluate the effect of Jardiance, including 10mg or 25mg once daily, added to standard of care compared with placebo on CV events in adults with T2D, at high risk of CV events and with less than optimised blood glucose control.